Pharmaceutical company Eli Lilly is developing an oral medication, Orforglipron, designed to aid in both weight loss and blood sugar control in adults with type 2 diabetes. Unlike current injectable treatments such as Ozempic and Wegovy, Orforglipron is a once-daily pill that targets the GLP-1 receptor, which helps regulate appetite and glucose levels.
In a Phase 3 clinical trial involving over 550 participants across multiple countries, those taking the highest dose of Orforglipron showed notable reductions in body weight and improved glycemic control.
Importantly, a large portion of participants achieved blood sugar levels below the diabetic range, indicating potential benefits for long-term diabetes management. The pill is a nonpeptide GLP-1 receptor agonist, meaning it is structurally different from peptide-based drugs like Semaglutide, which require injection.
This non-injectable format could broaden access to treatment for patients who prefer or require an oral option. Side effects reported in the trial included nausea, vomiting and diarrhea, which were generally mild and decreased over time. No significant liver-related safety issues were observed.
Eli Lilly expects to submit Orforglipron for regulatory approval for weight management by late 2025, and for type 2 diabetes indications in 2026. If approved, this would be one of the first oral GLP-1 receptor agonists available for both conditions. This development comes amid growing demand for obesity and diabetes treatments, as metabolic diseases continue to rise globally.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. The medication mentioned is still under investigation and has not been approved for public use. Always consult with a qualified healthcare professional before considering any new treatment or therapy.
